[ad_1]
The Sanitary Surveillance Agency (Anvisa) “decided to interrupt the clinical trial of the CoronaVac vaccine after a serious incident” on October 29. The agency did not provide details about what happened, but indicated that such incidents could include death, possibly fatal side effects, severe disability, hospitalization and other “clinically significant events.”
The Butantan Institute, one of the main medical research centers in Brazil and responsible for the CoronaVac vaccine, said this same Monday, November 9, that it will produce up to 100 million doses of coronavirus vaccines annually with the reforms that have already begun to be carried out in its plant in Sao Paulo, informed the governor of São Paulo, Joao Doria.
“It will be the first vaccine factory (against the new coronavirus) in the entire American continent” and this “is a historic day for Sao Paulo and Brazil,” said the governor during a press conference in which the details were explained. of the project, without taking into account that the health authorities were, on the same day, holding back the development of the tests until further notice.
The vaccine to be produced by the Butantan Institute is developed by the Chinese laboratory Sinovac, and the works that will allow the plant to mass-manufacture this antidote will be ready in September 2021.
In the coming weeks, the raw material for start the production of 40 million doses, which, while the reforms are finished, will be able to advance in other factoriesThe institute is already in operation, authorities said.
The director of the Butantan Institute, Dimas Covas, confirmed that the first batch with supplies to manufacture 1.2 million vaccines It will arrive no later than November 27 and delivery of the last of the remaining batches is scheduled for January 6.
Another 6 million doses of Coronavac will arrive ready from the Asian country. The first batch of 120,000 vaccines will arrive in Sao Paulo on November 20 and the second on December 30.
[ad_2]
